These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28786531)

  • 1. Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma.
    Gangadhar TC; Savitch SL; Yee SS; Xu W; Huang AC; Harmon S; Lieberman DB; Soucier D; Fan R; Black TA; Morrissette JJD; Salathia N; Waters J; Zhang S; Toung J; van Hummelen P; Fan JB; Xu X; Amaravadi RK; Schuchter LM; Karakousis GC; Hwang WT; Carpenter EL
    Pigment Cell Melanoma Res; 2018 Jan; 31(1):73-81. PubMed ID: 28786531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients.
    Kaneko A; Kanemaru H; Kajihara I; Mijiddorj T; Miyauchi H; Kuriyama H; Kimura T; Sawamura S; Makino K; Miyashita A; Aoi J; Makino T; Masuguchi S; Fukushima S; Ihn H
    J Dermatol Sci; 2021 Jun; 102(3):158-166. PubMed ID: 34049769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma.
    Mikoshiba A; Ashida A; Sakaizawa K; Kiniwa Y; Okuyama R
    J Dermatol Sci; 2020 Mar; 97(3):172-178. PubMed ID: 31987696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring Melanoma Using Circulating Free DNA.
    Diefenbach RJ; Lee JH; Rizos H
    Am J Clin Dermatol; 2019 Feb; 20(1):1-12. PubMed ID: 30374893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
    Ashida A; Sakaizawa K; Uhara H; Okuyama R
    Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients.
    Salvianti F; Massi D; De Giorgi V; Gori A; Pazzagli M; Pinzani P
    Cancer Biomark; 2019; 26(3):271-279. PubMed ID: 31524142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of the BRAF
    Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
    Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. USE OF CIRCULATING TUMOR DNA FOR DETECTION OF BRAF V600E MUTATION AND TREATMENT MONITORING IN MELANOMA PATIENTS.
    Shapochka D; Shapochka T; Seleznyov O; Matveeva A; Dudin V
    Georgian Med News; 2018 Mar; (276):76-81. PubMed ID: 29697386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and Impact of Embedding an Extended DNA and RNA Tissue-Based Sequencing Panel for the Routine Care of Patients with Advanced Melanoma in Spain.
    Castrejon N; Martin R; Carrasco A; Castillo P; Garcia A; Albero-González R; García M; Marginet M; Palau N; Hernández M; Montironi C; Clot G; Arance A; Alos L; Teixido C
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
    Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
    Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
    Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
    Almodovar K; Iams WT; Meador CB; Zhao Z; York S; Horn L; Yan Y; Hernandez J; Chen H; Shyr Y; Lim LP; Raymond CK; Lovly CM
    J Thorac Oncol; 2018 Jan; 13(1):112-123. PubMed ID: 28951314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of next generation sequencing-liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel-Trenaunay syndrome.
    Palmieri M; Pinto AM; di Blasio L; Currò A; Monica V; Sarno LD; Doddato G; Baldassarri M; Frullanti E; Giliberti A; Mussolin B; Fallerini C; Molinaro F; Vaghi M; Renieri A; Primo L
    Vascular; 2021 Feb; 29(1):85-91. PubMed ID: 32588787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
    Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
    Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.
    Valpione S; Gremel G; Mundra P; Middlehurst P; Galvani E; Girotti MR; Lee RJ; Garner G; Dhomen N; Lorigan PC; Marais R
    Eur J Cancer; 2018 Jan; 88():1-9. PubMed ID: 29175734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay.
    Olbryt M; Rajczykowski M; Bal W; Fiszer-Kierzkowska A; Cortez AJ; Mazur M; Suwiński R; Widłak W
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.
    Huang SK; Hoon DS
    Mol Oncol; 2016 Mar; 10(3):450-63. PubMed ID: 26778792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.